Hematopoietic reprogramming reflects the selective and evolutionarily conserved engagement of transcription factor networks that encode innate immune memory in long-lived stem cells.

The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. Clinical data show a nearly ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory ...

A study published in Nature looks at COVID-19 mRNA vaccines and the immune response to tumours during immunotherapy. Prof Andrew Beggs, MRC Senior Clinical Fellow and Consultant Colorectal Surgeon, ...

Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in ...

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq complianceSOUTH SAN FRANCISCO, Calif., Oct.

The poster for INSIGHT-003 and the Trial in Progress ePoster for TACTI-004 can be found at the Posters & Publications section of Immutep’s website.

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a ...